The Science of Memory Loss: Insights into Alzheimer’s Disease

Alzheimer’s disease (AD), the leading cause of dementia, is a growing public health crisis and one of the most burdensome diseases of the 21st century. Since the 2016 Seminar, substantial progress has been made in understanding AD’s complex pathogenesis, identifying genetic risk and protective fact...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnieszka Starzyk, Piotr Charzewski
Format: Article
Language:English
Published: Nicolaus Copernicus University in Toruń 2025-02-01
Series:Quality in Sport
Subjects:
Online Access:https://apcz.umk.pl/QS/article/view/57948
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823865218518745088
author Agnieszka Starzyk
Piotr Charzewski
author_facet Agnieszka Starzyk
Piotr Charzewski
author_sort Agnieszka Starzyk
collection DOAJ
description Alzheimer’s disease (AD), the leading cause of dementia, is a growing public health crisis and one of the most burdensome diseases of the 21st century. Since the 2016 Seminar, substantial progress has been made in understanding AD’s complex pathogenesis, identifying genetic risk and protective factors, and developing novel diagnostic biomarkers and therapeutic strategies. This review synthesizes findings from recent studies sourced from PubMed and Embase, focusing on advances in cerebrospinal fluid and blood-based biomarkers, imaging techniques such as PET and MRI, and therapeutic interventions. Current pharmacological treatments, including cholinesterase inhibitors and NMDA receptor antagonists, provide only symptomatic relief and fail to alter disease progression. Emerging therapies, such as monoclonal antibodies targeting amyloid-beta and tau proteins, show promise but are hindered by challenges in efficacy and safety. Neuroinflammation, driven by cytokines like IL-1β and TNF-α, is increasingly recognized as a central contributor to AD pathology, offering new therapeutic targets. Lifestyle modifications and multidomain prevention strategies, including exercise, cognitive training, and diet, demonstrate potential in reducing cognitive decline, particularly in at-risk populations. Despite these advancements, the development of effective disease-modifying treatments remains a pressing challenge. Continued innovations in biomarker research, therapeutic approaches, and personalized medicine are essential to improve outcomes for individuals with AD and to mitigate its growing societal impact.
format Article
id doaj-art-3b763a77475f45c8bf46aec25612fecc
institution Kabale University
issn 2450-3118
language English
publishDate 2025-02-01
publisher Nicolaus Copernicus University in Toruń
record_format Article
series Quality in Sport
spelling doaj-art-3b763a77475f45c8bf46aec25612fecc2025-02-08T08:25:08ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-02-013810.12775/QS.2025.38.57948The Science of Memory Loss: Insights into Alzheimer’s DiseaseAgnieszka Starzyk0https://orcid.org/0009-0002-8696-4187Piotr Charzewski1https://orcid.org/0009-0007-5170-3899Medical University of WarsawKozminski University Alzheimer’s disease (AD), the leading cause of dementia, is a growing public health crisis and one of the most burdensome diseases of the 21st century. Since the 2016 Seminar, substantial progress has been made in understanding AD’s complex pathogenesis, identifying genetic risk and protective factors, and developing novel diagnostic biomarkers and therapeutic strategies. This review synthesizes findings from recent studies sourced from PubMed and Embase, focusing on advances in cerebrospinal fluid and blood-based biomarkers, imaging techniques such as PET and MRI, and therapeutic interventions. Current pharmacological treatments, including cholinesterase inhibitors and NMDA receptor antagonists, provide only symptomatic relief and fail to alter disease progression. Emerging therapies, such as monoclonal antibodies targeting amyloid-beta and tau proteins, show promise but are hindered by challenges in efficacy and safety. Neuroinflammation, driven by cytokines like IL-1β and TNF-α, is increasingly recognized as a central contributor to AD pathology, offering new therapeutic targets. Lifestyle modifications and multidomain prevention strategies, including exercise, cognitive training, and diet, demonstrate potential in reducing cognitive decline, particularly in at-risk populations. Despite these advancements, the development of effective disease-modifying treatments remains a pressing challenge. Continued innovations in biomarker research, therapeutic approaches, and personalized medicine are essential to improve outcomes for individuals with AD and to mitigate its growing societal impact. https://apcz.umk.pl/QS/article/view/57948Alzheimer's diseasebiomarkersneuroinflammatoryneurodegeneration
spellingShingle Agnieszka Starzyk
Piotr Charzewski
The Science of Memory Loss: Insights into Alzheimer’s Disease
Quality in Sport
Alzheimer's disease
biomarkers
neuroinflammatory
neurodegeneration
title The Science of Memory Loss: Insights into Alzheimer’s Disease
title_full The Science of Memory Loss: Insights into Alzheimer’s Disease
title_fullStr The Science of Memory Loss: Insights into Alzheimer’s Disease
title_full_unstemmed The Science of Memory Loss: Insights into Alzheimer’s Disease
title_short The Science of Memory Loss: Insights into Alzheimer’s Disease
title_sort science of memory loss insights into alzheimer s disease
topic Alzheimer's disease
biomarkers
neuroinflammatory
neurodegeneration
url https://apcz.umk.pl/QS/article/view/57948
work_keys_str_mv AT agnieszkastarzyk thescienceofmemorylossinsightsintoalzheimersdisease
AT piotrcharzewski thescienceofmemorylossinsightsintoalzheimersdisease
AT agnieszkastarzyk scienceofmemorylossinsightsintoalzheimersdisease
AT piotrcharzewski scienceofmemorylossinsightsintoalzheimersdisease